1 |
Han TJ, Li JS, Luan XT, et al. Dietary fat consumption and non-Hodgkin's lymphoma risk: a meta-analysis[J]. Nutr Cancer, 2017, 69(2): 221.
|
2 |
Han TJ, Xu HZ, Li JS, et al. Leptin and its receptor in glucose metabolism of T-cell lymphoma[J]. Oncol Lett, 2018, 16(5): 5838.
|
3 |
Han TJ, Wang X. Leptin and its receptor in hematologic malignancies[J]. Int J Clin Exp Med, 2015, 8(11): 19840.
|
4 |
Wojciechowska J, Krajewski W, Bolanowski M, et al. Diabetes and cancer: a review of current knowledge[J]. Exp Clin Endocrinol Diabetes, 2016, 124(5): 263.
|
5 |
Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2014, 16(8): 707.
|
6 |
张曦, 饶军. 血液肿瘤的精准诊治[J]. 第三军医大学学报, 2020, 42(17): 1675.
|
7 |
郭一萌, 杨静, 严虹霞, 等. 二甲双胍对乳腺癌患者预后影响的Meta分析[J]. 肿瘤研究与临床, 2019, 31(1): 41.
|
8 |
Rodríguez-Lirio A, Pérez-Yarza G, Fernández-Suárez MR, et al. Metformin induces cell cycle arrest and apoptosis in drug-resistant leukemia cells[J]. Leuk Res Treatment, 2015, 2015: 516460.
|
9 |
Ramos Peñafiel C, Olarte Carrillo I, Ceron Maldonado R, et al. Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia[J]. Rev Med Chil, 2018, 146(7): 846.
|
10 |
Olarte Carrillo I, Ramos Peñafiel C, Miranda Peralta E, et al. Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia[J]. Hematology, 2017, 22(5): 286.
|
11 |
Ramos-Peñafiel C, Olarte-Carrillo I, Cerón-Maldonado R, et al. Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene[J]. J Transl Med, 2018, 16(1): 245.
|
12 |
Trucco M, Barredo JC, Goldberg J, et al. A phase Ⅰ window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin[J]. Pediatr Blood Cancer, 2018, 65(9): e27224.
|
13 |
陈惠丽, 马平, 陈艳丽, 等. 二甲双胍对K562细胞增殖、凋亡及糖酵解的影响[J]. 中国实验血液学杂志, 2019, 27(5): 1387.
|
14 |
Na YJ, Yu ES, Kim DS, et al. Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells[J]. Korean J Intern Med, 2021, 36(): S196.
|
15 |
Shi R, Lin J, Gong Y, et al. The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell[J]. Anticancer Drugs, 2015, 26(9): 913.
|
16 |
Renner K, Seilbeck A, Kauer N, et al. Combined metabolic targeting with metformin and the NSAIDs diflunisal and diclofenac induces apoptosis in acute myeloid leukemia cells[J]. Front Pharmacol, 2018, 9: 1258.
|
17 |
Huai L, Wang CC, Zhang CP, et al. Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway[J]. Biochem Biophys Res Commun, 2012, 422(3): 398.
|
18 |
Adekola KU, Dalva Aydemir S, Ma S, et al. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin[J]. Leuk Lymphoma, 2015, 56(2): 450.
|
19 |
Bruno S, Ledda B, Tenca C, et al. Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells[J]. Oncotarget, 2015, 6(26): 22624.
|
20 |
Rosilio C, Ben-Sahra I, Bost F, et al. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia[J]. Cancer Lett, 2014, 346(2): 188.
|
21 |
卢博, 桂书彦, 周欢欢,等. 二甲双胍抑制多发性骨髓瘤细胞增殖作用的实验研究[J]. 中国实验血液学杂志, 2017; 25(4): 1097.
|
22 |
仝佳音, 王冲, 刘延方, 等. 二甲双胍通过线粒体途径诱导人骨髓瘤细胞株U266细胞凋亡[J]. 中国实验血液学杂志, 2018, 26(2): 489.
|
23 |
Kocemba-Pilarczyk KA, Trojan S, Ostrowska B, et al. Influence of metformin on HIF-1 pathway in multiple myeloma[J]. Pharmacol Rep, 2020, 72(5): 1407.
|
24 |
Jagannathan S, Abdel-Malek MAY, Malek E, et al. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib[J]. Leukemia, 2015, 29(11): 2184.
|
25 |
Chang SH, Luo SH, O'Brian KK, et al. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study[J]. Lancet Haematol, 2015, 2(1): e30.
|
26 |
Wang W, Guan KL. AMP-activated protein kinase and cancer[J]. Acta Physiol, 2009, 196(1): 55.
|
27 |
Wang Y, Xu W, Yan Z, et al. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways[J]. J Exp Clin Cancer Res, 2018, 37(1): 63.
|
28 |
Zi FM, He JS, Li Y, et al. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models[J]. Cancer Lett, 2015, 356(2): 443.
|
29 |
Mishra AK, Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells[J]. Leukemia, 2019, 33(11): 2695.
|
30 |
Weiss BM, de Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients[J]. Blood, 2009, 113(22): 5418.
|
31 |
Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study[J]. Blood, 2009, 113(22): 5412.
|
32 |
Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance[J]. N Engl J Med, 2002, 346(8): 564.
|
33 |
Boursi B, Mamtani R, Yang YX, et al. Impact of metformin on the progression of MGUS to multiple myeloma[J]. Leuk Lymphoma, 2017, 58(5): 1265.
|
34 |
Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy[J]. Cell Death Dis, 2012, 3(3): e275.
|
35 |
Chukkapalli V, Gordon LI, Venugopal P, et al. Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells[J]. Oncotarget, 2018, 9(30): 21166.
|
36 |
Naserian M, Ramazani E, Iranshahi M, et al. The role of SAPK/JNK pathway in the synergistic effects of metformin and dacarbazine on apoptosis in raji and Ramos lymphoma cells[J]. Curr Mol Pharmacol, 2018, 11(4): 336.
|
37 |
Tseng CH. Metformin is associated with a lower risk of non-Hodgkin lymphoma in patients with type 2 diabetes[J]. Diabetes Metab, 2019, 45(5): 458.
|
38 |
Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study[J]. Leuk Lymphoma, 2017, 58(5): 1130.
|
39 |
Singh AR, Gu JJ, Zhang Q, et al. Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma[J]. Cancer Metab, 2020, 8: 10.
|